🔍 New Study Highlights Why Consistency Matters in AI-Driven Aneurysm Detection
A recent peer-reviewed study published in Nature Scientific Reports (June 6, 2025) reveals a critical challenge in AI-based aneurysm detection: performance instability under varying CT imaging conditions. The research evaluated an FDA-cleared commercial AI and found that its accuracy deteriorated significantly at both low and high radiation doses—particularly when filtered back projection (FBP) was used. While radiologists maintained near-perfect detection across all conditions, the AI missed key aneurysms in 7.1% of scans, with a striking 97.6% miss rate for 2 mm basilar artery aneurysms.
📖 Read the full study here: https://lnkd.in/gEPnZevb
💡 PurpleAI: Designed for Real-World Consistency in Aneurysm Detection At PurpleAI, we recognize the complexities of real-world imaging—and we've engineered our solution, Hyper Insight - ANEURYSM™, to meet that challenge head-on.
✔️ Product Names: Medical Insight + Brain Aneurysm Hyper Insight-ANEURYSM™
🧠 Our Advantage: Maintains high sensitivity even for mid-to-large aneurysms (≥5 mm: 92.68%), outperforming comparable FDA-cleared products.
Built on multi-center validation (872 cases across 3 leading hospitals) and a hybrid CNN-RNN model optimized for CTA variability.
Supports clinicians with probability maps and location-specific predictions to enhance diagnostic efficiency and speed.
📊 Performance Snapshot: MFDS approval completed for clinical use in Korea Compatible with contrast-enhanced Brain CTA Currently supports rupture risk stratification roadmap
🔬 While emerging AI tools struggle with consistency, PurpleAI is committed to delivering robust, reproducible, and clinically validated performance—ensuring better outcomes for patients and more confidence for physicians.
#AIinHealthcare #NeuroimagingAI #CerebralAneurysm #Radiology #MedicalAI #StrokeCare #PurpleAI